Exelixis

YTD

ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,077

Employees1,077

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,077

Employees1,077

EXEL Key Statistics

Market cap

11.67B

Market cap11.67B

Price-Earnings ratio

15.71

Price-Earnings ratio15.71

Dividend yield

—

Dividend yield—

Average volume

2.60M

Average volume2.60M

High today

$46.68

High today$46.68

Low today

$44.31

Low today$44.31

Open price

$46.30

Open price$46.30

Volume

2.26M

Volume2.26M

52 Week high

$49.62

52 Week high$49.62

52 Week low

$33.76

52 Week low$33.76

Stock Snapshot

The current Exelixis(EXEL) stock price is $44.31, with a market capitalization of 11.67B. The stock trades at a price-to-earnings (P/E) ratio of 15.71.

On 2026-04-25, Exelixis(EXEL) stock moved within a range of $44.31 to $46.68. With shares now at $44.31, the stock is trading 0.0% above its intraday low and -5.1% below the session's peak.

Trading activity shows a volume of 2.26M, compared to an average daily volume of 2.6M.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $33.76.

EXEL News

TipRanks 2d

Exelixis and Merck Advance Key Phase 3 Kidney Cancer Trial, Setting Up a New Catalyst for EXEL

Exelixis (EXEL) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

Simply Wall St 2d

Does Exelixis Gain Quiet Competitive Leverage From a Rival’s Kidney Cancer Setback?

Earlier this week, Exelixis drew attention after a report said a rival’s triple‑drug kidney cancer regimen failed in a Dow Jones pharma update, highlighting Exe...

Simply Wall St 3d

The Tactical Trio Blueprint For Solid Balance Sheet And Fundamentals

With inflation, energy shocks and bond yields all in focus, many investors are looking for companies that are not only surviving the noise but also backed by st...

Analyst ratings

48%

of 21 ratings

Buy

47.6%

Hold

47.6%

Sell

4.8%

More EXEL News

TipRanks 5d

Exelixis price target raised to $45 from $44 at Barclays

Barclays raised the firm’s price target on Exelixis (EXEL) to $45 from $44 and keeps an Equal Weight rating on the shares. The firm adjusted ratings and targets...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.